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The gut microbiome consists of a complex amalgamation of diverse bacterial species in the 
human gastrointestinal (GI) tract. Proliferation and normobiosis of bacteria are dependent on the 
nutrient intake supplied by the host, intra-and-inter metabolite signaling, crosstalk between 
neighboring species and environmental signals, and cues based on the geographical location 
along the GI tract. With the recent explosion of gut microbiome research, several research groups 
have identified and elucidated the critical role gut-metabolites play in modulating an individual’s 
normal physiology and/or contribute to several diseased states, including  neuropsychiatric 
disorders such as Major Depressive Disorder (MDD), and Generalized Anxiety Disorder (GAD) 
and neurodegenerative disease such as Parkinson’s Disease (PD) and Alzheimer’s Disease. The 
purpose of this review is to systematically identify recent advancements of major bacteria phyla 
such as Baceteroidetes and Firmicutes and its relevant genus and species in health and disease, 
and how some of the specific metabolites produced by the respective genus and species may 
mediate neuropsychiatric disorder. Further exploration of such metabolites and its dominant 




Parkinson’s Disease (PD), Major Depressive Disorder (MDD), Generalized Anxiety Disorder 
(GAD), gamma amino butyric acid (GABA), Human Microbiome Project (HMP), 




The gut microbiome is an exception to the common phrase that the whole is greater than the sum 
of its parts. The microbiome is established early in life and this dynamic relationship between the 
microbial flora and its host are subjected to environmental triggers and certain genetic 
predisposition which influence the microbiome and thus in-turn influence the overall health 
status of host. Therefore, in understanding this symbiotic relationship between the microbiome 
and host, comprehension of the dominant microbiota and its metabolites may provide insight into 
the pathogenesis of some diseases and expose avenues for therapeutic intervention. It is the 
 2 
purpose of this review to compile the major bacterial species and genera within the gut 
microbiome to date, and to identify the metabolites they produce with the best of our knowledge. 
Furthermore, this review seeks to identify gaps and challenges in current literature, which may 
provide insight into the therapeutic targets in gut microbiome. 
 
3. The Gut Microbiome 
 
The human gastrointestinal tract is inhabited by a diverse assortment of organisms including 
bacteria, fungi and viruses. The composition of such microorganisms, within the gastrointestinal 
system are collectively known as the “gut microbiome.” To understand the complex role of the 
microbiome NIH in early 2007, conducted a major study known as the Human Microbiome 
Project (HMP) to identify and map the microbial ecosystem in order to elucidate its role in health 
and disease. Identification and classification of species within the human gut have been carried 
out by through two primary sequencing methodologies, shotgun and 16S amplicon 
sequencing(ref.). With the data generated by HMP, researchers around the globe have been able 
to identify numerous microorganisms involved in pathogenesis of several diseases.  
 
Bacteria are the predominant microorganisms in the human microbiota coexisting in a nearly 1:1 
ratio in regard to human cells (1). In total, there are nearly 1000 different species of bacteria in 
the gut microbiome (2). The microbiome, once established early in life, tends to remain 
relatively constant however its composition is not static (3). The gut microbiome exhibits inter-
individualistic differences and is also subject to divergence from the core microbiome over time 
due to factors such as: diet or dietary change, diseased state, and/or use of medication. This 
microbiome has been implicated in host-microbes’ metabolic functions, protection from 
pathogens, and education of the immune system (2). One landmark study determined the major 
components of the gut microbiome to be from five bacterial phyla: Bacteoridetes, Firmicutes, 
Actinobacteria, Proteobacteria, and Verrucomicrobia (7). Of particular interest, are the two 
major phyla, which were identified in that study; Baceteroidetes and Firmicutes, which 
comprised approximately 90% of the gut microbes (7). In this review, these phyla will be the 
subject of analysis for available knowledge on metabolic function, and its role in 
neuropsychiatric disorder.  
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4. Inclusion Criteria 
 
Two phases were utilized during this literature review. During the first phase, the designated 
phyla of bacteria were determined by the reports from Arumugam et al., in 2011 along with other 
concurring reports (7-11). After determining the major phyla, bacteria were further 
taxonomically organized based on Bergey’s Manual of Systematic Bacteriology Volume 3 and 
Volume 4, with additional cross-referencing with NCBI’s taxonomy database and the list of 
prokaryotic names with standing in nomenclature database. Furthermore, reported species were 
then compared to the International Code of Nomenclature of Prokaryotes to determine species, 
which have been accepted as valid. Only species which were considered valid were reported in 
this review. Minor amendments were also made based on updates to the species and 
categorizations performed since that publication in other relevant literature. The complete list of 
explored genera are composed in Figure 1.  
 
Figure 1. Phylogenetic tree of genera explored in this review. The two initial nodes represent the divergence of 
bacterial organisms within the phyla Bacteroidetes and Firmicutes, respectively. The terminal branches indicate the 
genera of bacterial organisms under exploration.  
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Search words included taxonomic organization, genus then species, the phrase “gut 
microbiome,” and finally the taxonomic organization again in quotations. For example: 
“Bacteroides vulgatas ‘gut microbiome’ ‘Bacteroides vulgatas.’” A time range between 2005 
and 2019 was set. Abstracts of publications matching those keywords were then screened for 
each matching key word. Each species was then characterized by the amount of resources 
devoted to its understanding. Search results greater than 100 in the last 15 years were considered 
abundant, whereas less than 100 search results in the last 15 years were considered sparse.  
 
The second phase of this review targets dysbiosis of the major bacterial phyla involved in 
neuropsychiatric disorder and neuroinflammatory processes. Key words used in order to yield 
those articles included the genus of the bacteria as in phase one, then the disease or disorder, so 
that it appeared as follows “Genus Disease ‘Disease’.” The diseases and disorders included in the 
search were generalized anxiety disorder, major depressive disorder, and Parkinson’s disease. A 
similar method was utilized in order to obtain search results for metabolites/molecules associated 
with the aforementioned pathologies. Those metabolites/molecules include serotonin, 
epinephrine, norepinephrine, dopamine, GABA, kynurenine, and glucuronic acid.  
 
Finally, species of bacteria in the two major phyla that did not yield significant search results 
were not reported. Furthermore, genera that contained only one species, which yielded sparse 
search results were also excluded. For example, the genera Xylanibacter and Rikenella were not 
reported. However, it should be stated that they did receive exploration throughout this review.   
 
5. Composition of the Gut Microorganisms 
 
The gut microbiome is home to a variety of bacteria, which reside in the series of hollow organs 
spanning from the oral cavity to the anus. There is abundant evidence supporting a few dominant 
phyla within the gastrointestinal tract (7-11). Those dominant phyla include Bacteroidetes and 
Firmicutes, which compose, on average, 90% of gut microbiota. However, this statistic alone 
does sufficiently elucidate the gut microbiome composition. Bacteroidetes may vastly outnumber 
Firmicutes, or vice versa, depending on demographic and geographic factors such (11). 
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Furthermore, Bacteroidetes composition appears to exhibit inter-individual variation; whereas 
the Firmicutes appear to vary over time within individuals (8).  
 
Although Bacteroidetes and Firmicutes are the dominant phyla, further diversity within the gut 
microbiome is promoted by a variety of factors. For instance, Bacteroidetes and firmicutes may 
compete for the same available resources, thus limiting dominance of other at the specific 
location. Another common phenomenon involves certain bacteriophages that play a vital role in 
inhibiting the growth of certain species in the human body (5). Regional conditions of the 
gastrointestinal tract also serve as selective pressures, which determine what microorganisms 
flourish. The duodenum is subjected to exposure to rapidly changing pH, digestive enzymes, 
bile, as well as varying levels of oxygen suggesting predomination of genera such as 
Lactobacillus, Eubacterium, and Streptococcus in the duodenum (12). In comparison, this 
composition changes somewhat in the jejunum and ileum where microaerophilic strains such as 
Enterococcus, Lactobacillus, Streptococcus, and Gammaproteobacteria, are more common 
(12,13).  The large intestine is mildly acidic with stable pH and it is also a predominantly 
anaerobic therefore supporting the growth of obligate anaerobes strains such as Bacteroides, 
Prevotella, Rikenella, Lachnospiracae, and Ruminococcus (14).  
 
5.1 Bacteroidetes  
 
The taxonomic organization of the Bacteroidetes phylum has been subject to change in the last 
twenty years with the development of novel classification techniques. According to Bergey’s 
Manual of Systematic Bacteriology, the Bacteroidetes phylum is composed of four Gram-stain-
negative, rod-shaped classes. It includes: Bacteroidia, Flavobacteriia, Sphingobacteriia, and 
Cytophagia (15). Bacteroidia itself has five families, classified in the order Bacteroidales, those 
families include Bacteroidacea, Rikinellaceae, Porphyromonadaceae, Prevotellaceae, and 
Marinilabiliaceae (15). Recent work determining the composition of the gut microbiome 
determined the most common bacterial genera of the small intestine. Those genera included the 
Bacteroides, Parabacteroides, Alistipes, and Prevotella (9, 11). Of the samples obtained by 
Arumugam et al, the Bacteroides genera were disproportionately more abundant than any other 
genus within that phylum (9). However, one recent study showed that this relationship may be 
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expected as Prevotella and Bacteroides are, to some extent, antagonistic to one another. For 
example, mice were colonized by Prevotella copri, Bacteroides thetaiotaomicron, or both 
species. Individually, Prevotella copri and Bacteroides thetaiotaomicron flourished, but when  
combined in the same environment, populations decreased for both species (16).  
5.1.1 Bacteroides 
The Bacteroides genus is the largest of the genera constituting the family Bacteroidacea (15). It 
is comprised of >10 species of anaerobic, nonmotile, saccharolytic bacteria (15). Multiple 
sources have found Bacteroides vulgatus, Bacteroides thetaiotaomicron, Bacteroides coprocola, 
Bacteroides caccae, Bacteroides uniformis, Bacteroides fragilis, Bacteroides eggerthii, and 
Bacteroides massiliensis, Bacteroides pyogenes, Bacteroides salyersiae, and Bacteroides nordii 
were detected in stool samples (16,17). Of those found, the predominant species appeared to be 
Bacteroides vulgatus, Bacteroides fragilis, Bacteroides thetaiotaomicron, Bacteroides uniformis, 
and Bacteroides caccae (17,18). However, it should be noted that individual variation in diet, 
such as increased fiber intake, vegan, vegetarian, or omnivorous may account for some 
discrepancies (18-20). Furthermore, differences in location of samples may also account for 
individual differences in Bacteroides species (20). Bacteroides eggerthii, among other species of 
bacteria, has also been implicated in the development of colitis in mouse models (21). 
Bacteroides fragilis and Bacteroides thetaiotamicron have also been the subject of study in 
regard to promoting intreaepithelial lymphocytes in the epithelial lining of the colon (22).  
5.1.2 Alistipes 
The Rikenellaceae family contains the genera Alistipes and Rikenella. Alistipes can be further 
classified into eight species of nonmotile, Gram-negative rods, which are obligate anaerobes 
(15). Those species are listed in Table 1.   
As a whole, Alistipes have been of some interest in studying gut microbial composition in 
obesity patients, and Alistipes may play a role in ease of weight loss (23). Increased levels of 
Alistipes have also been identified in relation to MDD (24). However, current literature on 
specific species of Alistipes is more limited. For example, available publications for Alistipes 
putredinis seem to only identify its presence in stool samples (25, 26) or being used as a 
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reference genome. Alistipes finegoldii has recently been implicated as a colitis-protecting species 
within the gut microbiome of mice (21). Alistipes onderdonkii has also been the subject of 
interest as it has been shown to promote intraepithelial lymphocyte production (22). Alistipes 
shahii has been correlated with increased species richness, as well as elevated fruit consumption 
(27).  
5.1.3 Prevotella 
The family Prevotellaceae contains two genera, Prevotella and Xylanibacter (15). The family 
can be further subdivided into >20 anaerobic, rod-shaped, saccharolytic species indicated in 
Table 1.   
Review of the available literature showed that specific roles of species in health and disease is 
limited to a small pool of species. However, information regarding the genus Prevotella is more 
abundant. As a whole, Prevotella has been implicated in obesity and weight loss, as a reduction 
in Prevotella may also be related to ease of weight loss (23). Prevotella has also been reported to 
primarily inhabit mucosal sites, such as the oral cavity, respiratory tract, and the gastrointestinal 
tract. Given its diverse nature, Prevotella appears to have a “finger in every pie.” Recent studies 
and literature reviews have focused on the role of Prevotella in mediating an immune response 
resulting in inflammatory diseases such as rheumatoid arthritis, periodontitis, bacterial vaginosis, 
asthma, COPD, and inflammatory bowel disease (28, 29, 30). For example, a recent study on 
Chinese subjects showed increased levels of Prevotella melaninogenica and Prevotella copri 
have both been associated with the development of Ankylosing Spondylitis (31). Prevotella 
copri has also been strongly associated in the exacerbation of colitis in murine models and the 
onset of untreated rheumatoid arthritis (29). The topic of rheumatoid arthritis and Prevotella 
yielded a wealth of information. HIV was also associated with increased prevalence of specific 
lineages of Prevotellaceae, Prevotella stercorea and Prevotella coprii (32). During the course of 
this review a multitude of species of Prevotella were implicated in the oral microbiome and 
development of disease, such as Prevotella pallens, Prevotella maculosa, and Prevotella 




Multiple species from Bacteroides have been relocated to the more appropriate family 
Porphyromonadaceae. This family is characterized as predominantly anaerobic, saccharolytic, 
nonmotile, gram-negative rods (15). Porphyromonadacea is composed of eight genera including: 
Porphyromonas, Barnesiella, Dysgonomonas, Paludibacter, Petrimonas, Proteiniphilum, 
Tannerella, and Parabacteroides (15). Of interest is the Parabacteroides genus, which is 
comprised of eight species of bacteria listed in Table 1.  
Parabacteroides distasonis has received significantly more attention than any of the other 
species. Parabacteroides distasonis has been implicated in playing a role in reduction of 
cytokines in murine models of acute and chronic colitis induced by dextran sulphate sodium 
(35). However, another recent study reported that Parabacteroides distasonis may play a role in 
promoting colitis (21). Parabacteroides goldsteinii has also been of some interest, with a few 
recent studies aimed on the role of Parabacteroides goldsteinii in obesity and hepatitis. For 
example, one study determined that the oral administration of Parabacteroides goldsteinii to 
high-fat-diet mice resulted in increased adipose tissue thermogenesis (36). Furthermore, this 
bacterium was correlated with reduced inflammation and improved insulin sensitivity (36). It is 
possible that if underlying mechanisms are elucidated in this process, that it may be of some use 
in maintenance of obesity, colitis, or even diabetes mellitus. Parabacteroides johnsonii research 
is also abundant and diverse. One study focused on the effects of administration of Resveratrol 
on glucose homeostasis and gut microbial composition (37). Those results showed that the level 
of Parabacteroides johnsonii were reduced, along with an alteration in the Bacteroidetes to 
Firmicutes ratio (37). Another study observed the differences in the gut microbiome of subjects 
with alopecia aureate, in which enriched levels of Parabacteroides johnsonii, among other non-
Parabacteroides species, were detected (38). The study of Parabacteroides merdae has been 
diverse and abundant as well. Studies on Parabacteroides merdae have ranged from enzymatic 
analysis, to its effects on hypertension, and to a review on its relation to the ketogenic diet in 
seizure patients (39-41).  
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Phylum Genus Species Associated Literature 
Bacteroidetes 
    
Bacteroides 
vulgatus 16, 17, 18 
thetaiotamicron 16, 17, 18, 22 
coprocola 16, 17, 114 
caccae 16, 17, 18 
uniformis 16, 17, 18 
fragilis 4, 6, 16, 17, 18, 22  
eggerthii 16, 17, 21 
massiliensis 16, 17, 114 
pyogenes 16, 17 
salyersiae 16, 17 
nordii 16, 17 
      
Alistipes 




ihumii, indistinctus, inops, timonensis Scarce results 
  
Prevotella 
pallens 33, 34 
melaninogenica 31 
coprii 16, 29, 31, 32, 114 
buccalis 33, 34 
maculosa 33, 34 
stercorea 32 
veroralis, albensis, denticola, multiformis,  
corporis, disiens, aurantica, falsenii,  
intermedia, nigrescens, bergensis, oris, salivae, bryantii, 
multisaccharivorax, baroniae, buccae, dentalis, enoeca, 
pleuritidis, tomonensis, loescheii, shahii, brevis, 
ruminicola, amnii, bivia, dentasini, fusca, jejuni, marshii, 
nanceiensis, oryzae, oulorum, paludivivens, 
saccharolytica, scopos 
Scarce results 
      
Parabacteroides 
merdae 39, 40, 41 
distasonis 35 
goldsteinii 36 
jhonsonii 37, 38 
gordonii, chartae, chichillae, faecis Scarce results 
 
Table 1. Compiled list of the species within each genera of the Bacteroidetes. Each genus and its respective 








5.2 Firmicutes  
 
The Firmicutes phylum has also been subject to change in the last decade, having previously 
been comprised of three classes, according to Bergey’s Manual of Systematic Bacteriology 
Volume 3. These three classes included: Bacilli, Clostridia, and Erysipelotrichia (42). However, 
four more additions to the class have been made since that publication. Those classes were 
obtained from the NCBI Taxonomy Browser and include: Negativicutes, Limnochordia, 
Thermolithobacteria, and Tissierellia. The majority of these classes are gram positive, though a 
few exceptions are made (42). Bacilli is further subdivided into the orders: Bacillales and 
Lactobacillales. Lactobacillales is comprised of six families, of which focus will remain on a 
specific subset. Importantly, Lactobacillales contains the family Streptococceae, which includes 
the genera Streptococcus, Lactococcus, and Lactovum. Based on the study performed by 
Arumugam et al., 2013, focus will be placed on Streptococcus, along with: Faecalibacterium, 
Roseburia, Blautia, Coprococcus, Ruminococcus, Eubacterium, Dorea, Subdoligranulum, 
Anaerostipes, Holdemania, Anaerotruncus, Acidaminococcus, Megasphaera, Dialister, and 
Coprobacillus (9). 
 
The class Clostridia is further subdivided into the orders: Clostridiales, Halanaerobiales, and 
Thermoanaerobacterales. Of significance, the Clostridiales order is comprised of the 
Ruminococcoceae, Lachnospiriceae, and Eubacteriaceae families. Within the Ruminococcaceae 
family are the genera Faecalibacterium, Ruminococcus, Subdoligranulum, and Anaerotruncus. 
Within the Lachnospiriceae family is Roseburia, Blautia, Coprococcus, Dorea, Anaerostipes, 
Within the Eubacteriaceae family is the genus Eubacterium.  
 
Erysipelotrichia is composed of the order Erysopelotrichiales, which is further made up of the 
family Erysopelotrichaceae. Importantly, this family contains the genera Coprobacillus and 
Holdemania.  
 
The class Negativicutes is comprised of three orders: Acidiminococcales, Selenomonadales, and 
Veillonellales. Particular attention will be made to the orders Acidiminococcales and 
Veillonellales. Acidiminococcales is importantly composed of the family Acidiminococcaceae, 
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which contains the genus Acidiminococcus. Veillonellales contains the family Veillonellaceae, 
which contains the genera Megasphaera and Dialister.  
 
5.2.1 Faecalibacterium 
The genus Faecalibacterium is composed of nonmotile, strictly anaerobic, rod shaped cells of 
varying length, some of which are gram negative staining (42). This genus contains one species, 
Faecalibacterium prausnitzii. However, as the sole species of its genus this bacterium has 
garnered significant attention in gut microbiome. Faecalibacteirum prausnitizii is widely 
regarded as the most prominent bacteria in the gastrointestinal tract, accounting for 
approximately 5% of faecal microbes (43). This statistic has been supported by another study, 
which proposed that the abundance and transcriptional activity of Faecalibacterium prausnitzii 
appears to be more important than the mere presence or absence of that species (44).  
Publications in this time range tend to focus on the role of Faecalibacterium prausnitzii in 
production of butyrate and inflammatory processes. This metabolite has been implicated as an 
anti-inflammatory in the colonic mucosa (45); as such Faecalibacterium prausnitzii has been 
subject to study in inflammatory processes such as irritable bowel disease (44, 46). More 
specifically, Faecalibacterium prausnitzii was shown to have a protective effect against 
development of Crohn’s disease in murine models via blockage of NF- KB and IL-8 (47). 
5.2.2 Ruminococcus 
 
The genus Ruminococcus is classified as strictly anaerobic, chain-forming cocci, which are 
gram-stain-positive in some cases and gram-stain-negative in many cases (42). Ruminococcus 
contains eleven species, which are listed in Table 2.  
 
Much of the work on species of Ruminococcus has focused on the role that Ruminococcus albus, 
Ruminococcus flavifaciens, and Ruminococcus champanellensis species play in digestion of 
complex polysaccharides such as cellulose (48, 49). This cellulolytic action aids in the continual 
recycling of the most abundant biopolymer in nature, which explains why many resources have 
gone into the understanding of these species. Other species of Ruminococcus are non-
cellulolytic, such as Ruminococcus bromii. Ruminococcus bromii has also been focused on for its 
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role in degradation of starch in the human GI tract. Ruminococcus bromii has been shown to 
degrade starches that are typically resistant to degradation earlier in the GI tract, as well as 
improve the ability of other species of starch-digesting species of bacteria to digest resistant 
starches (50). Furthermore, this species has been shown to increase in abundance to exposure to 
resistant starches (51). Ruminococcus gnavus has been the subject of study in Crohns disease and 
Ulcerative Colitis (52). The abundance of this species in these diseases may be related to its 
ability to affect mucin expression in the intestines of mouse and human models, as well as utilize 
mucin-derived glycans for metabolic purposes (53-55). Another study found that Ruminococcus 
gnavus appears to be more aerotolerant than its classification may suggest (55). These reports 
may be two sides of the same coin, as increased mucin expression by intestinal goblet cells may 
protect the bacteria from the reactive oxygen species involved in IBD as well as providing an 
ample growth medium. However, studies have not yet shown whether the abundance of 
Ruminococcus gnavus is coincidental or incidental to the worsened disease state. Thus, further 
investigation is required. Of interest, one publication determined that the amplification of RNA 
derived from Ruminoccocus gnavus was significantly greater than that of other indicated species 
in Crohns disease and IBD (44). Thus, small changes in the abundance of Ruminoccocus gnavus 
in the intestine may have greater effects than other species (44). Similar to Ruminococcus 
gnavus, Ruminococcus torques is a mucin-degrading bacterial species, which has been 
implicated in subjective, worsened symptom reports by individuals with IBD (56). 
Ruminococcus torques has also received some attention in regard to its ability to produce 
butyrate, and in one study was shown to have reduced abundance in Crohns disease subjects 
(57). Ruminococcus lactaris search results were abundant, however, multiple mentions of the 
phrase “Ruminococcus lactaris” were in passing or in regard to a species that bore resemblance 
to Ruminococcus lactaris. Ruminococcus faecis shares a similar story, although it has received 




Roseburia is a genus composed of five slightly curved, rod-shaped, gram-negative or gram-
variable, motile, obligate anaerobic species, which are also known to hydrolyze starch (42). The 
five species, which can be found in Table 2. As a whole, these species have received moderate 
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attention due to their role in the production of the short chain fatty acid, butyrate (58, 59). Given 
this reputation, these species have been the subject of multiple studies.  
 
One recent study sought to understand factors that can affect the Firmicutes to Bacteroidetes 
ratio via administration of a whole-grain barley vs brown rice diet (58). The results of that 
experiment showed a gradual increase in both the Roseburia faecis and Roseburia intestinalis 
species, among other Firmicutes (58). This point serves to show that the gut microbiome is not 
static, and changes in diet may alter the normal gut microbiome ratio. Furthermore, Roseburia 
faecis has been shown to produce a bacteriocin-like substance against Bacillus subtilis, which 
may allow it to successfully compete with other bacteria in the intestines of its host (60).  
 
Roseburia hominis was recently determined to affect host gene expression in the innate immune 
system, the gut barrier, and T cells of murine models (61). More specifically, Roseburia hominis 
was shown to upregulate gene activity in Roseburia hominis mono-colonized mice (61). 
Furthermore, Roseburia hominis levels have been shown to be reduced in subjects with IBD 
(61). That reduction of the gut barrier-promoting bacterial species could bely an effect on the 
severity of IBD (61). Of interest, search results for Roseburia hominis yielded a patent for 
production of a probiotic used for modulating host immunity, satiety, and IBD, to name a few 
(62).  
 
The extent of study of Roseburia inulinivorans appears to revolve around its role as a butyrate-
producing bacterium (58, 59). One recent study, for example, showed that along with reduced 
levels of Ruminococcus torques, Roseburia inulinivorans abundance in the intestines of Crohns 
disease subjects was reduced in those with positive C reactive protein levels (57). Continuing 
with the theme of butyrate, Roseburia intestinalis is no exception. This species has been the 
focus of multiple studies regarding its ability to synthesize butyrate. In one study, Roseburia 
intestinalis colonization in murine models was shown to be a protective factor from 
atherogenesis (63). In that study, Roseburia intestinalis mice exhibited a 30% reduction in the 
area of atherosclerotic plaques (63). It was suggested that this reduction was mediated via the 
fourfold production of butyrate when compared to a core bacterial community (63). This species 
was also determined to be one of the major inhabitants of intestinal mucins, which may be due to 
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The genus Blautia is a relatively novel genus and has been met with some scrutiny. In this 
review, Blautia will be covered as though it was entirely accepted. This genus is composed of 13 
species of bacteria, which are characterized as mostly Gram-positive, anaerobic, and 
coccobacillus shaped (65-69). The species included in this genus are listed in Table 2.   
 
Information on specific species of Blautia is difficult to determine given the instability of the 
current acceptance of Blautia. Thus, available literature tends to look at Blautia on the genus-
level, rather than on species level. As previously mentioned, there are some dominant bacteria in 
the human host, which may differ based on geographic location. In one study, researchers 
focused on the group Clostridium coccoides in a Japanese population, and the subgroups and 
species that compose it (69). That group has been reported to contain several genera, including 
Eubacterium, Blautia, Clostridium, and Dorea, to list a few. Fecal samples obtained from their 
subjects showed that the genus Blautia was the most common subgroup of intestinal microbes 
regardless of age (69). Furthermore, Blautia was also found to decrease in abundance with age 
(69). The species of Blautia included in that study were: Blautia hydrogenotrophica, Blautia luti, 
Blautia obeum, Blautia schinkii, Blautia hansenii, Blautia producta, and Blautia coccoides (69). 
This study also supported previous hypotheses that overall counts of Clostridium coccoides 
group between children and adults is relatively stable (69). However, it also seemed to oppose 
the idea that the gut microbiome is of a stable composition, since the Clostridium coccoides 
group diminished into later age (69). These results suggest that the gut microbiome is still subject 
to change throughout the human lifetime, which supports the need to further refine the study of 
stability of the populations of the gut microbiome depending on age. Blautia hydrogenotrophica 
has received some attention due to its ability to synthesize acetate from hydrogen (70). It may be 
speculated that this carbon-cycling activity within the host could contribute to the growth of 
species that utilize acetate. In contrast, it could also contribute to the loss of species that compete 




Coprococcus is a genus composed of three species of bacteria characterized as nonmotile, 
obligately anaerobic, chemoorganotrophic, Gram-stain positive cocci (42). These bacteria 
include: Coprococcus eutactus, Coprococcus catus, and Coprococcus comes. Altogether, these 
species are known for their production of short chain fatty acids, such as butyrate, acetate, formic 
acid, and propionic acid (42).  
 
Coprococcus eutactus has been studied for its varied presence, or decreased abundance, in 
subjects with IBS. Coprococcus eutactus has been shown to occur normally within the intestines 
of healthy control subjects compared with IBS subjects (71). Another recent study appeared to 
confirm this difference; Coprococcus eutactus was shown to have reduced abundance in subjects 
with IBS who also hosted Ruminococcus torques (56). As previously mentioned, Ruminococcus 
torques is a mucin-degrading species, thus it may occur in competition with Coprococcus 
eutactus, or subject to competition by another species of bacteria. Therefore, it may be worth 
investigating the localization of the Coprococcus eutactus to determine its abundance and 
dependence on mucin as well as its aerotolerance. One study suggested a relationship between 
Gram-negative bacteria and Gram-positive bacteria such as Coprococcus eutactus. In that study, 
Bdellovibrio bacteriovorus, a predator of Gram-negative bacteria, were introduced to rat models, 
which resulted in a gradual increase in the abundance of Coprococcus eutactus (72). However, 
that study was unable to determine the exact cause of the increase in that species. Coprococcus 
catus has been the subject of study in regard to its production of short chain fatty acids in 
multiple studies including its potential role in obesity of children, ability to survive and produce 
short chain fatty acids in varying pH, and possible effect on preeclampsia (73-75). Coprococcus 
comes also appears to have been subject to studies interested primarily in its role in the 









The genus, Dorea, is composed of two species characterized as nonmotile, obligately anaerobic, 
chemoorganotrophic, Gram-stain positive rods (42). These bacteria include: Dorea longicatena, 
Dorea formicigenerans.  
 
Dorea longicatena has received some attention, and this species is considered to have an 
abundance of information. Similar to other species of bacteria in different genera, Dorea 
longicatena has been the subject of study in regard to Crohns disease. This species was recently 
found to increase in abundance in the ileal mucosa of subjects experiencing Crohns disease 
remission (77). In another study, both Dorea longicatena and Dorea formicigenerans were 
implicated in cytokine activity; an abundance of these species was associated with elevated 
levels of interferon gamma in response to fungal-derived stimuli (78). As stated by those authors, 
the ability of Dorea longicatena and Dorea formicigenerans to metabolize sialic acid of mucins 




Anaerostipes is a genus composed of four species of nonmotile, Gram-positive in exponential 
phase but not in the stationary phase, obligately anaerobic rods, which sometimes occur in chains 
of 2-4 cells (42). These species are also known to produce the short chain fatty acid, butyrate 
(42). These species can be found in Table 2.   
 
Anaerostipes caccae has received the most attention within the genus Anaerostipes. One recent 
study utilized Anaerostipes caccae and Akkermansia muciniphila co-cultures to determine that 
mucin-degrading species can promote the growth of butyrogenic species by providing a 
nutritional supply (79). Furthermore, the presence of the Anaerostipes caccae induced changes in 
the expression of the mucin-degrading genes via upregulation of the response regulator 
Amuc_1010 (79). This study again highlights one of the many possible relationships that gut 
commensal bacteria can provide to other species and could elucidate the previously mentioned 
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increase in levels of Ruminococcus gnavus. Anaerostipes hadrus also has an abundance of 
information regarding its role as a butyrate-producing bacterium (41, 80).   
 
Anaerostipes butyraticus was isolated in 2010 from the cecal content of a broiler chicken, which 
may contribute to the sparse results for this topic (81). However, this species has received some 
attention for its reputation as a “hyper-butyrate producer” (82). It seems likely that more 
attention will focus on this species and other producers of short chain fatty acids as more 
knowledge about the role of SCFA’s in pathogenesis is elucidated.  
 
5.2.8 Eubacterium 
The genus Eubacterium is composed of >15 different species of bacteria, characterized as Gram-
positive, obligately anaerobic, chemoorganotrophic rods (42). These species are also known to 
produce the short chain fatty acids butyrate, acetate, and formate (42). These species can be 
found in Table 2.  
Eubacterium coprostanoligenes is well-known for its role in the reduction of cholesterol to 
coprostanol (83, 84). As such, it has been utilized in studies in order to determine its effects on 
hypercholesterolemia, as is the case with the series of studies of hypercholesterolemia by Li et 
al., 1995, 1996, and 1998. In the first study, rabbits received an oral administration of 
Eubacterium coprostanoligenes, which resulted in a significant decrease in the plasma 
cholesterol concentration (85). Furthermore, the hypocholesterolemic effect lasted for another 34 
days after the last oral administration (85). However, the effect of oral administration of 
Eubacterium coprostanoligenes on cholesterolemia still appears to be somewhat unclear; as the 
follow-up studies determined that oral administration of Eubacterium coprostanoligenes to hens 
and murine models was unable to affect plasma cholesterol levels (86, 87). Current research on 
the pathways and the enzymes involved in this conversion are not fully elucidated. Furthermore, 
the impact on the formation of cholesterol-derived hormones; glucocorticoids, 
mineralocorticoids, androgens; and species capable of reducing cholesterol in the gut 
microbiome is a topic that has not seen much exploration (88).   
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Eubacterium limosum has been implicated as a species that increases in abundance throughout 
age, thus supporting the notion that the gut microbiome has a dynamic composition that may 
change with age. In that study, the abundance of Eubacterium limosum was determined to be 10-
fold of that compared to the two younger groups (89). At this point in time, much work has been 
devoted to understanding the metabolic relationship between Eubacterium ramulus and dietary 
polyphenols, but Eubacterium limosum has also received some attention as well. However, 
studies of this topic have been confounded by the inability to control the host microbiome, as 
well as account for the variability in the host. One recent study focused on the role of 
Eubacteirum limosum and Eubacterium ramulus in the catabolism of polyphenols (90). 
Eubacterium ramulus was determined to have the capacity to metabolize the polyphenols 
Xanthohumol, 8-prenylnaringenin, and desmethylxanthohumol in vitro (90). Furthermore, 
Eubacterium ramulus utilizes the product 8-prenylnaringenin formed by Eubacterium limosum to 
create O‐desmethyl‐α,β‐dihydroxanthohumol (90). This relationship also supports the 
cooperativity exhibited by species of bacteria, which occurs in the host.  
 
The species Eubacterium rectale has received significantly more attention than any other species 
in the genus Eubacterium. This abundance may be, in part, due to the role of Eubacterium 
rectale in production of the short chain fatty acid butyrate (91). One recent study found that 
abundance of Eubacterium rectale increased in one group of subjects that were producing high 
amounts of butyrate in response to the gradual administration of a resistant starch diet (91). 
However, in another group of subjects deemed the “elevated” group, abundance of 
Bifidobacterium adolescentis and Ruminococcus bromii were found rather than the Eubacterium 
rectale (91). It is possible that this difference is due to the sample size, thus further exploration 
of this topic will be required.   
 
Eubacteirum ventriosum has been found in association with obesity in multiple studies (92, 93). 
In a recent study on obese Japanese subjects, this species along with Blautia 
hydrogenotorophica, Coprococcus catus, Eubacterium ventriosum, Ruminococcus bromii, 
and Ruminococcus obeum were found to be associated with obesity (92). However, the 
directionality of this relationship was unable to be established. This again reinforces the need for 
continued study of these organisms and the effect on the development of disease. This study did 
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appear to confirm a previous association made in 2012 in a study performed on monozygotic 
twins (94). This study also determined that higher BMI twins had increased abundances of 
Eubacterium ventriosum and Roseburia intestinalis (93).  
Although literature regarding Eubacteirum eligens and Eubacterium siraeum are considered 
abundant, the majority of the literature utilized the species as a representative species for 
Eubacterium or provided passing mention of the species. It is also likely that the inclusion of the 
phrase “gut microbiome” is including additional search results that are absent of the phrase 
“Eubacterium eligens” or “Eubacterium siraeum.”  
5.2.9 Acidaminococcus 
 
The genus Acidaminococcus is composed of two species of coccoid, Gram-negative, nonmotile, 
anaerobic, chemo-organotrophic cells (42). These two species include Acidaminococcus 
fermentans and Acidaminococcus intestini.  
 
Of the aforementioned species, the most well-studied is Acidaminococcus fermentans. This 
species has received moderate attention for its role as one of the most prominent bacteria 
involved in the hydrolysis of amino acids (94, 95). This species was recently found to occur in 
abundance in fecal samples of subjects with ankylosing spondylitis, along with Parabacteroides 
distasonis, Eubacterium siraeum, Acidaminococcus fermentans and Prevotella copri (96). 
Although, aforementioned reports have suggested that Prevotella copri may exhibit an 
antagonistic response to Bacteroides thetaiotamicron. One may speculate that if such 
competition occurs in the gut microbiome, that the prevalence of another bacteria that is 
antagonistic to a competitor of Acidaminococcus fermentans may account for the increased 
abundance of this, or other, species.   
 
5.2.10 Megasphaera 
Megasphaera is a genus, which is comprised of nine species of obligately anaerobic, nonmotile, 
Gram-negative, short-chain-fatty-acid-producing cocci (42). Those nine species can be found in 
Table 2.  
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The species Megasphaera elsdenii has been of particular interest in ruminant animals, as it was 
initially identified in the rumen of cattle (97). There is some available literature on the role of 
this species in the gut of non-ruminant animals such as kittens, rats, and pigs (97-99). One study 
from 2003 identified changes in the abundance of this species in fecal samples of kittens, which 
showed reduced percentages of that sequenced bacteria in fecal samples at twelve weeks of age 
(98). Taken together, the role of this butyrate-producing bacteria may still have an unidentified 
role in the human gut microbiome.  
Megasphaera massiliensis yielded scarce search results, since its isolation in 2013 from the stool 
of an HIV infected patient (100). However, this species has seen some recent interest due to its 
role in the production of butyrate and valeric acid. In one study, this bacterium was shown to 
have the strongest enhancing function on histone deacetylases in comparison to Roseburia 




The genus Dialister is composed of five species of obligately anaerobic, nonmotile, small, Gram-
negative coccobacilli (42). Those species can be found in Table 2.  
 
Dialister invisus was initially isolated from the human oral cavity, although it has also been 
isolated in the intestine and has been implicated in IBS and DM1 (44, 103, 104). One recent 
publication reporting that Dialister invisus occurred in abundance within subjects with IBS (44). 
However, this species was relatively inert and did not exhibit gene expression within the host 
(44). This report would suggest that Dialister invisus is either non-growing or a dead population 
and therefore is not contributing to the disease state. This study also highlights an important 
aspect of the gut microbiome; it is not sufficient for one species to be abundant in the gut, but it 
must also be transcriptionally active. One study associated Dialister invisus abundance with 
increased permeability of the gut in Diabetes Mellitus Type 1 subjects but were unable to 
elucidate the specific role this species played (104). Thus, it is possible that Dialister invisus may 
contribute to dysbiosis and the disease state. 
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Table 2. Compiled list of the genera of Firmicutes and their associated species. The major genera explored in 
this study were subdivided into their corresponding species. Each species has associated literature, unless otherwise 




Phylum Genus Species Associated Literature 
Firmicutes 
      
Faecalibacterium prausnitzii 43, 44, 45, 46, 47, 124 
  
Ruminococcus  
bromii 50, 51, 92 
champanellensis 48, 49 
faecis 58 
flavefaciens 48, 49 
torques 56, 57 
gnavus 44, 52, 53, 54, 55, 126, 127 
albus, bicirculans, callidus, gauvreauii, lactaris Scarce results 
  
Roseburia 
faecis 58, 60 
hominis 61, 62, 125 
inulinivorans 57, 58, 59 
intestinalis 58, 63, 64, 93, 125 
cecicola Scarce results 
  
Blautia 
coccoides, hansenii, hominis, luti, obeum, producta, shinkii 69 
hydrogenotrophica 69, 70, 92 
caecimuris, faecis, glucerasei, stercoris, wexlerae Scarce results 
  
Coprococcus 
eutactus 56, 71, 72 
catus 6, 73, 74, 75, 92 
comes 76 
  
Dorea longicatena 77, 78 formicigenerans 78 
  
Anaerostipes 
butyraticus 81, 82 
caccae 79 
hadrus 80 
rhamnosivorans Scarce results 
  
Eubacterium 
coprostanoligenes 83, 84, 85, 86, 87 




ventriosum 92, 93 
aggregans, barkeri, callenderi, eligens, halli, multiforme, oxidoreducens,  




Acidaminococcus fermentans 94, 95, 96 intestini Scarce results 
  
Megasphaera 
elsdenii 97, 98, 99, 100 
massiliensis 101, 102 
cerevisiae, hexanoica, indica, microniciformis, paucivorans, stantonii, 
sueciensis Scarce results 
  
Dialister invisus 44, 103, 104, 105 microaerophilus, pneumosintes, propionicifaciens, succinatiphilus Scarce results 
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6. Neuropsychiatric Disorders and Gut Dysbiosis 
 
Indeed, gut microbiome dysbiosis has been linked to multiple facets of systemic disorders. 
However, more recent studies have sought to understand the relationship between the gut 
microbiome and neuropsychiatric disorder such as, Major Depressive Disorder, and Generalized 
Anxiety Disorder and as a comorbidity of neurodegenerative disorders such Parkinson’s disease. 
One founding hypothesis for the “gut-brain axis” was proposed by Braak and colleagues (105). 
They suggested a relationship between neuropsychiatric disorder and the gut was linked by the 
connection of the intestines via parasympathetic fibers from the vagus nerve to the spinal cord. In 
the gut, sensory information is registered via the nodose ganglion, and is then transmitted to the 
nucleus tractus solitarius of the brain. Braak and colleagues cemented their hypothesis in the 
wake of isolating Lewy bodies (protein aggregates composed primarily of alpha synuclein and 
ubiquitin) from the enteric nervous system, spinal cord, prefrontal cortex, and mid-brain of 
subjects with early PD (105). Following that study, it was shown that the injection of alpha 
synuclein into the gut wall in rat models migrated to the brain stem through the vagus nerve 
(106). The aforementioned hypothesis addresses the “highway” that connects the gut to the brain 
and does not account for the microbiota and their potential influence on that axis. Thus, we 
incorporate the findings of a few recent studies. The first showed that changing diet to a 
combination of high fat and high sugar diet in rat models resulted in dysbiosis of the gut 
microbiome. They suggested that dysbiosis may account for activation of microglia in the nodose 
ganglia that causes an inflammatory response that is responsible for changes in vagal afferent 
fibers (107).  
 
Other explanations for the relationship between the gut microbiome and nervous system have 
explored bacterial production of molecules that may act as local neurotransmitters in the gut. For 
example, serotonin has been shown to mediate the enteric nervous system, as well as activity of 
the vagus nerve. This notion has been supported by the recent work by Neufeld and colleagues 
(108).  In that study, they demonstrated that administration of oral selective serotonin reuptake 
inhibitors increases the rate of action potential production in the vagal nerve afferents harvested 
from the jejunum of mouse models. Furthermore, direct administration of SSRIs such as 
sertraline or fluoxetine to the lumen of the jejunum also resulted in increased rate of action 
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potentials (108). For example, Lactobacillus reuteri has been shown to be capable of producing 
GABA from L-Glutamate, and Clostridia has been shown to produce GABA from glutamic acid 
(110, 111). Not only have bacteria been shown to directly produce these molecules, they have 
also been shown to influence their synthesis within cells of the gastrointestinal tract. A study by 
Asano and colleagues have shown that bacteria, such as Clostridia, possessing β glucuronidase 
are capable of liberating conjugated neurotransmitters including dopamine and norepinephrine in 
the intestine of mouse models (112). Of importance, these bacteria are capable of producing or 
influencing production of neurotransmitters, which are implicated in disorders such as PD, 
MDD, and GAD. Thus, we will now explore which bacterial phyla are capable of producing such 
metabolites.  
 
6.1 Bacteroidetes in Neuropsychiatric Disorder and Metabolic Products 
 
One recent publication showed a reduction in the level of Bacteroidetes in subjects with MDD. 
However, they also indicated that bacteria belonging to the genus Prevotella were found to have 
increased in abundance in the obtained fecal samples (112). Although important, it should be 
underscored to report all observable changes in the microbiome, rather than generalized changes 
in abundances of bacteria. There were no indications that Prevotella abundance is altered or 
affects GAD. However, one publication reported that levels of Prevotella copri in comparison to 
control were elevated in subjects with PD (113). Given this information, and the role that 
Prevotella have been reported to play in other inflammatory diseases, that changes in the level of 
this species could induce inflammatory changes contributing to the pathogenesis of PD (28-31).  
 
The genus Alistipes has been implicated in MDD. In one recent study, it was shown that 
Alistipes, along with Enterobacteriaceae had increased in abundance in patients with that 
disorder (24). There was little available information to support a role for Alistipes in GAD. 
However, the abundance of the genus Alistipes along with other genera has also been associated 
with subjects with PD when compared to healthy controls (114, 119).  
 
Literature regarding the role of Bacteroides in MDD is available. However, according to one 
recent comprehensive review, there are conflicting results on the roles of Prevotella, Alistipes, 
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and Bacteroides in MDD (115). These genera have all been shown to have results that support 
both increases and decreases in abundance in subjects with MDD (115). Thus, further research 
into the roles of these genera will be necessary to accurately determine their roles in this 
disorder. One study has shown that abundance of Bacteroides in fecal samples has been shown to 
increase in subjects with GAD (116). In regard to PD, one recent study showed reduced 
abundance of multiple species of Bacteroides including Bacteroides massiliensis and 
Bacteroides coprocola in fecal samples of subjects with PD compared to healthy controls (114). 
As a whole, the genus Bacteroides was also found to be reduced in abundance (114). Another 
older study also found that levels of Bacteorides fragilis in subjects with PD were reduced in 
abundance when compared to controls (4). However, these results conflict with an earlier study 
that showed that the genus Bacteroides increased in abundance in fecal samples obtained from 
PD patients (6). It is apparent that Bacteroides dysbiosis is present when comparing diseased-
state subjects to controls. However, further analysis will be required to determine the exact role 
of the species and genus Bacteroides. It may be reasonable to conclude, that although relative 
decreases at the genus level are being recorded, increases in abundance of one or more species in 
that genus may be hidden indicators of the diseased state. This statement therefore highlights the 
caution that should be taken when reporting genus-level changes in abundance.  
 
There was little information available regarding the role of the genus or species of 
Parabacteroides in GAD and MDD. However, the genus Parabacteroides has been shown to 
increase in abundance in fecal samples from subjects with PD when compared to healthy 
controls in multiple studies (117-119). Thus, there may be room for exploration of species of 
Parabacteroides and how the changes in their relative abundance relate to PD.  
 
As previously stated, if bacteria in the class Clostridia or genus Lactobacillus, have been shown 
to produce compounds that affect the brain-gut axis, a loss of corresponding species could 
possibly confer negative effects for the host. However, available literature has not supported this 
assertion for the genus Prevotella. There was no available indication that Prevotella was capable 
of producing neurotransmitter-like compounds including GABA, dopamine, serotonin, 
norepinephrine, or epinephrine. That genus has also not had any indication in the ability to 
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produce short-chain-fatty acids. There were no reports of species of Prevotella with β 
glucuronidase activity.  
 
In contrast to Prevotella, the genus Alistipes may play a role in the metabolism of the 
neurotransmitters GABA and serotonin. In one review and one recent experiment, Alistipes was 
reported to utilize the enzyme glutamate decarboxylase (121, 122). That enzyme is responsible 
for the production of GABA (121). Furthermore, another study also suggested that Alistipes may 
be capable of producing indole, a derivative of tryptophan (24). Thus, it is worth speculating that 
this production of indole from tryptophan may cause a reduction in the availability of tryptophan 
for serotonin synthesis. However, indole has also been shown to be re-converted back into 
tryptophan. Thus, an alternative suggestion may be necessary. Perhaps, an over-abundance of 
Alistipes may cause an imbalance the normal formation and conversion of tryptophan to indole. 
If that occurs, it is reasonable to then suggest that and over-abundance of Alistipes could 
contribute to a decrease in tryptophan available for serotonin synthesis. That deficit in serotonin, 
or the aforementioned production of GABA may then contribute to the pathogenesis of 
neuropsychiatric disorder. Although, there is some evidence that the genus Alistipes may play a 
role in the reactivation and level of serotonin in the gut. Thus, this activity and the role of 
Alistipes in the gut microbiome will require further exploration. It would be reasonable to 
propose that an over-abundance of Alistipes in the gut microbiome may contribute to deficits in 
serotonin or other metabolites that contribute to the pathogenesis of neuropsychiatric disease. 
Furthermore, this proposal is supported by multiple publications that have found a positive 
correlation between the over-abundance of the genus Alistipes in patients with depression (24, 
120).  
 
Two available sources reported that both Bacteroides and Parabacteroides may be capable of 
producing GABA, the former was able to further specify that those species contained the gadB 
and gadC genes (121, 122). The latter study was able to utilize Parabacteroides and Bacteroides 
obtained from fecal samples of healthy individuals to draw the conclusion that they are, indeed, 
capable of producing GABA (122). Thus, abnormalities or dysbiosis may result in abnormal 
amounts of synthesized GABA in the gut that could potentially contribute to neuropsychiatric 
disorder. There have also been reports that the subspecies Bacteroides fragilis is capable of 
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producing the short chain fatty acid propionate from succinate. Information regarding the role of 
Bacteroides and Parabacteroides on the production of serotonin was sparse. Parabacteroides 
and Bacteroides also yielded sparse search results when reviewing available literature for 
kynurenine and the kynurenine pathway.  
 
Taken together, it may appear that the role of Bacteroidetes in the synthesis or reactivation of 
molecules and compounds associated with neuropsychiatric disorder is supported. Thus, further 
study will be required to elucidate the roles that species of the aforementioned genera play in that 
biosynthesis. Possible future directions may focus on the effect of those synthesized molecules 
on local nervous tissues such as the vagus nerve.  
 
6.2 Firmicutes in Neuropsychiatric Disorder and Metabolic Products 
 
Clostridia and Lactobacillus are two genera within the phylum Firmicutes. As previously 
mentioned, these species have already been implicated in the neuropsychiatric disorder. Thus, it 
is worth exploring the possibility that other well-cited Firmicutes may also be associated with 
neuropsychiatric disorder.  
 
In one recent study, reduced abundance of Faecalibacterium prausnitzii was shown to be 
associated with MDD (24). However, other supporting studies are scarce, and further exploration 
will need to be done before confirming this species role.  There was no available information to 
support the role of this species in GAD. However, one study has shown an association between 
reduced abundance of Faecalibacterium in colonic mucosa samples of PD subjects (6). Thus, it 
may be worth investigating the metabolic roles of this species, as well as its function within the 
mucosa of the intestine. As previously stated, it is also possible that this species is subject to 
predation or may be antagonistic to other species of bacteria. Thus, relationships between this 
species and other gut commensals should also be explored.  
 
The genus Ruminoccocus was one of several genera shown to be elevated in healthy controls 
compared to subjects with active MDD (24). Furthermore, Ruminococcus was also shown to be 
of decreased abundance in responded MDD (24). However, this genus suffers the same lack of 
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supporting studies as Faecalibacterium. There was no supporting information for the role of this 
genus in GAD or PD.  
 
As reported by Jiang et al. in 2015, Roseburia was also shown to be of increased abundance in 
subjects with active and responded MDD (24). Again, recent exploration of the role of this genus 
in depression and MDD remains relatively unexplored. There was no supporting information for 
the role of this genus in GAD. However, one study showed an increased abundance of Roseburia 
in healthy controls when compared to PD (6). Unfortunately, additional studies supporting this 
association were scarce. Thus, future directions may focus on the role of this species in PD 
progression. It may also be worth exploring the relationships between this gut microorganism 
and other commensal bacteria. Through that method, it may be possible to determine whether 
this species abundance is the result of PD progression or bacterial predation or antagonism.  
 
In the same study, the genus Blautia was shown to increase in abundance in subjects with active 
and responded MDD (24). However, there was a lack of supporting studies regarding the 
association between Blautia and MDD. There was no available information regarding the role of 
Blautia in GAD. However, levels of Blautia have been shown to be altered in subjects with PD 
compared with healthy subjects. In that study, Blautia was significantly more abundant in those 
healthy controls (6). However, there were no supporting studies to confirm this role. Thus, there 
may be some association between PD and reduced abundance of Blautia, but that will require 
further exploration. Furthermore, other factors such as metabolic roles and antagonistic effects 
between bacteria should be explored.   
 
Information regarding the role of Coprococcus in MDD and GAD was scarce. However, this 
genus may be open to exploration in those disorders given the aforementioned roles of the 
species Coprococcus catus and Coprococcus comes in the production of short chain fatty acids. 
To the contrary, decreased levels of Coprococcus has been associated with PD. In the study 
performed by Keshavarzian and colleagues in 2015, Coprococcus was shown to be reduced in 
abundance in fecal samples of PD subjects when compared to healthy controls (6). 
Unfortunately, there was no available information to support or refute this relationship. Thus, 
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further exploration of this relationship will be required to determine the extent of the role of 
Coprococcus in PD.  
 
Similar to the Bacteroidetes, Firmicutes may also play a role in metabolites associated with 
neuropsychiatric disorder. The genus Faecalibacterium has been implicated in decreased levels 
of serotonin. As one study has shown, after modeling IBS by administration of dinitro-benzene 
sulfonic acid, Faecalibacteirum prausnitzii was administered to the colon of germ-free murine 
models. After administration, reduced levels of serotonin were recorded (123). If this species is 
truly associated with decreases in GI serotonin, further exploration should focus on determining 
the metabolic capabilities of Faecalibacterium prausnitzii. Faecalibacterium prausnitzii have 
also been explored for their role in the production of butyrate (45). There was no available 
information regarding the role of this genus in synthesis or metabolism of GABA, dopamine, 
epinephrine, or norepinephrine. Faecalibacterium prausnitzii was not associated with beta-
glucuronidase activity. Furthermore, one study exposed this species to growth conditions 
restricted to glucuronic acid, and determined 
 
Faecalibacterium praustnitzii showed a limited range of growth from none to very poor (123). 
Therefore, it is unlikely that this species contains the enzymes necessary to utilize glucuronic 
acid as an energy source.  
 
It is possible that serotonin level within the gut may also be influenced by the presence of 
Ruminococcus. Specifically, Ruminococcus gnavus has been well-documented in utilizing the 
enzyme tryptophan decarboxylase (125). This enzyme is responsible for converting tryptophan 
into tryptamine. Tryptamine, then may act as a neurotransmitter capable of stimulating further 
release of serotonin by enterochromaffin cells of the GI (125). It would not be unreasonable then, 
to suggest that serotonin is capable of affecting the gut-brain axis mediated by the vagus nerve. 
There was no available information regarding the role of Ruminococcus in synthesis or 
metabolism of GABA, dopamine, epinephrine, or norepinephrine. However, there are reports of 
beta-glucuronidase activity in Ruminococcus gnavus (126). With this activity, it is possible that 
Ruminococcus gnavus is capable of reactivating glucuronide-conjugated compounds. 
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Searching the available literature for Roseburia did not yield information regarding a role in 
serotonin, dopamine, GABA, norepinephrine, or epinephrine synthesis or metabolism. However, 
there was available information to indicate beta glucuronidase activity in Roseburia intestinalis 
and Roseburia hominis when exposed to differing growth media (124). This varied activity may 
suggest an environmental or dietary sensitivity, which determines the level of activity of this 
enzyme.  
 
Similar to Ruminococcus, Blautia has also been proposed to contain a tryptophan decarboxylase 
homolog capable of producing tryptamine (125). If correct, this could have a similar effect on 
enterochromaffin cell serotonin production in the GI as Ruminococcus. However, no available 
sources indicated a role in GABA, dopamine, epinephrine, norepinephrine, or glucuronic acid 
synthesis or metabolism.  
 
Similarly, the genera Eubacterium, Coprococcus, Megasphaera, and Dialister did not yield any 
associations with production of dopamine, serotonin, GABA, norepinephrine, epinephrine or 
glucuronic acid. However, Megasphaera elsdneii has been shown to be involved in metabolism 
of amino acids in the human GI. Thus, it may be possible that species of Megasphaera function 
to reduce the availability of amino acids to be used by the surrounding tissue. Furthermore, 
utilization of the amino acids by these species supports competition between other genera that 
are also capable of utilizing amino acids, such as Acidaminococcus and Lactobacillus (127).  
 
7. Therapeutic Applications 
 
Consider a generic extended release medication. Now, imagine that delayed release agent but 
living in unison with the commensal bacteria of the GI. In that case, the medication may be 
continuously synthesized in the GI of the host and be reabsorbed by the intestinal wall. 
Essentially, this method achieves the same effect of an oral extended-release therapeutic, but it 
allows for continued synthesis of the medication within the host. However, this is not a 
permanent change, as we know the commensal bacteria continuously divide and die within the 
host. The genetically modified bacteria are no different. This exemplifies the use of bacteria in 
personalized medicine. Each bacterium can be uniquely modified to produce certain metabolites 
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at a regulated rate. Furthermore, the metabolites produced have been specifically chosen for that 
bacteria and have been shown to provide therapeutic effect. The modification of Escherichia coli 
(E.coli) Nissle by Isabella et al., in 2018 is one example of utilization of a bacterial species for 
treatment of a disease; in this case, it was synthesized for management of phenylketonuria (128). 
Previous studies have demonstrated E.coli Nissl as a probiotic, was a model candidate for 
treatment of GI conditions, given its effects on IBS (128). Furthermore, this species is readily 
eliminated from the body within a period of one week and does not colonize the human GI tract 
(128). With some modification based on the conditions of the GI tract, the Escherichia coli 
Nissle SYNB1618 strain was produced for management of phenylketonuria (128). This strain 
was genetically engineered to utilize phenylalanine ammonia lyase and L-amino acid deaminase 
in order to degrade phenylalanine in the GI (128). Although it has not yet been tested in human 
clinical trials, is has shown some promise in decreasing phenylalanine levels in the intestines of 
phenylketonuria mouse models (128). Non-human primate models have also shown support for 
the benefits of that same strain in improving phenylketonuria (128).  
 
One similar route of therapy has been taking markets, grocery stores, and other health-focused 
stores by storm. That form of therapy is colloquially known as over-the-counter probiotics. 
These probiotics are carefully composed of species of bacteria, which have been determined to 
produce metabolites that have some therapeutic action. The aforementioned patent for a probiotic 
containing Roseburia hominis, exemplifies this new form of therapy, which has been proposed as 
a treatment for a wide range of disorders. Some of those disorders include modulating host 
immunity, satiety, and IBD (62). However, probiotics themselves are not a “one shoe fits all” 
form of therapy. If we accept that each individual has a unique gut microbiome, then each person 
may require a carefully formulated probiotic in order to avoid dysbiosis. This is one of the 
hallmark limitations of a generalized probiotic therapy. Although Roseburia hominis may 
produce beneficial metabolites within the host, it may only be possible to administer it to 
individuals who already have a high prevalence of Roseburia hominis. Administration of this 
probiotic to an individual with a relatively low level of Roseburia hominis could result in 
dysbiosis and subsequent worsening of their condition. However, the previous statement will 
require further study and clinical trials in order confirm or rule out that precaution.  
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Another strategy for therapeutics is cell-based therapy, in which living cells are administered to 
the host for some therapeutic purpose. The stem cell derivatives, among other types of cells, can 
promote healing through two major pathways after administration; via replacement of damaged 
cells or recruitment of local cytokines and growth factor (129). This form of delivery directly 
corresponds to the idea of administration of commensal bacteria. However, a key difference 
between bacteria and the cells, lies in integration. The bacteria are not truly becoming “one” with 
the host, but merely living in symbiosis with it and replacing something that was previously 
there. However, in stem-cell therapy sometimes the cells become part of the host by replacing 
defective cells. From a lay-man’s perspective, it is also possible the idea of ingesting a probiotic 
on a regular schedule may appear less stressful than changing themselves at the cellular level. 
Furthermore, a once weekly oral probiotic may be more appealing than taking an oral or injected 
medication for management of disease.  
 
Here, we propose a bridge between the two previously mentioned forms of bacterial metabolic 
therapy. It may be possible to create a bacterial strain that can produce metabolites with 
therapeutic capabilities, which can colonize in the gut with some assistance from a regularly 
scheduled probiotic. One outstanding difference between the proposed method of a probiotic 
bacterial metabolite-therapy and the applied Escherichia coli Nissle SYNB1618 strain is the 
ability to colonize. If species of the host commensal bacteria of the GI can be identified, then it 
may be possible to engineer a personalized strain of bacteria that mimics the host microbiome. 
Given the capacity for the original species to live in symbiosis in the host, the modified strain 
may be able to survive in the host and produce the metabolites necessary for treatment of the 
disease for that individual.  
 
Indeed, we have identified several bacterial genera that are reportedly capable of producing and 
reactivating key metabolites for the synthesis of other biologically active molecules. Those 










glutamate decarboxylase, GABA production 121, 122 
indole production 24 
Bacteroides glutamate decarboxylase, GABA production 121, 122 




tryptophan decarboxylase 125 
beta glucuronidase 126 
Roseburia beta glucuronidase 124 
Blautia tryptophan decarboxylase 125 
 
Table 3. Metabolic Activity of Bacteroidetes and Firmicutes by Genera. Above contains the major genera 
involved in affecting compounds identified in this study, including GABA, Serotonin, and glucuronic acid 




The purpose of this review has been to identify key bacterial phyla, genus and species in in 
current literature, and then determine which of those species are capable of producing or 
reactivating metabolites that correspond to neuropsychiatric disease. This has been done in order 
to find species that may be genetically modified and utilized for live probiotic-based therapy.  
Although multiple species of bacteria were identified and characterized based on their abundance 
in available literature, we were not able to readily identify species that could be used for 
therapeutic purposes. It is possible that species of bacteria, which are capable of producing the 
aforementioned metabolites were not part of the original inclusion criteria. Furthermore, it is 
possible that the aforementioned species and genera are known to be involved in production of 
other metabolites not explored in this review. Despite the scarcity of information at the species 
level, we were able to determine multiple genera that may show some promise in the future for 
development of therapeutic agents.  
 
This review was not without limitations, and those limitations will be explored hereafter. Within 
the design of the review, the number of publications needed in phase one was chosen based on 
the fact that research in the gut microbiome is a growing field. The number chosen did not 
represent recent or current trends in research that may have shown increased exploration in 
 33 
certain areas. Therefore, species or genera considered scarce at the time of this review may reach 
criterion in a few months. Despite this, we encourage continued research in all of the 
aforementioned species, especially those which have shown scarce results.  
 
In regard to the role of bacteria and their association with neuropsychiatric disorder, continued 
work is still needed. Multiple studies, some of which were reported here, and many that were not 
reported, were correlational. Although correlation may be an important step in identifying a 
relationship, it should be followed with experimental design in order to elucidate an actual causal 
relationship. For example, does the increase in abundance of a certain bacterial specie or strain in 
patients with MDD, truly cause the disease or is there an underlying predatory relationship with 
decrease in abundance of another commensal neighboring species. By exploring the relationship 
between host and microbe and innovating creative strategies to study the interactions i.e. 
developing novel animal models, metagenomic/metabolomic algorithms, and imaging tools, we 
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